Corrigendum to "Comparison of naturally acquired antibody responses against the C-terminal processing products of Plasmodium vivax Merozoite Surface Protein-1 under low transmission and unstable malaria conditions in Sri Lanka" [International Journal for Parasitology 37 (2007) 199-208] (DOI:10.1016/j.ijpara.2006.09.002);Comparison of naturally acquired antibody responses against the C-terminal processing products of Plasmodium vivax Merozoite Surface Protein-1 under low transmission and unstable malaria conditions in Sri Lanka

International Journal for Parasitology

Volumn 37, Issue 2, 2007, Pages 199-208

  Wickramarachchi, Thilan ^a   Illeperuma, Ruwan J ^b   Perera, Lakshman ^c   Bandara, Sumith ^c   Holm, Inge ^d   Longacre, Shirley ^d   Handunnetti, Shiroma M ^c   Udagama Randeniya, Preethi V ^a  

^a UNIVERSITY OF COLOMBO   (Sri Lanka)

^b UNIVERSITY OF COLOMBO   (Sri Lanka)

^c OPEN UNIVERSITY OF SRI LANKA   (Sri Lanka)

^d INSTITUT PASTEUR   (France)

Author keywords

Antibody switch; Immuno epidemiology; Low transmission; MSP 1 C terminal fragments; Plasmodium vivax; Sri Lanka; Unstable malaria

Indexed keywords

IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN M ANTIBODY; MEMBRANE PROTEIN; PROTEIN P19; PROTEIN P42; RECOMBINANT PROTEIN;

ANTIBODY; ANTIGEN; COMPARATIVE STUDY; ENDEMISM; EPIDEMIOLOGY; HEMOPARASITE; IMMUNE RESPONSE; IMMUNOASSAY; MALARIA; PARASITE TRANSMISSION; PROTEIN; PROTOZOAN;

ADOLESCENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACULOVIRUS; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; ENDEMIC DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC POLYMORPHISM; HUMAN; MAJOR CLINICAL STUDY; MALARIA; MEROZOITE; MICROSCOPY; PARASITE TRANSMISSION; PLASMODIUM VIVAX; PROTOZOAL INFECTION; SRI LANKA; URBAN AREA; VIRUS RECOMBINANT;

ASIA; EURASIA; SOUTH ASIA; SRI LANKA;

PLASMODIUM VIVAX;

EID: 33846096772     PISSN: 00207519     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpara.2007.01.008     Document Type: Erratum

References (44)

1. Ministry of Health, 2001. Annual Health Bulletin Sri Lanka. Ministry of Health, Sri Lanka, pp. 47-49.
2. Al-Yaman F., Genton B., Kramer K.J., Chang S.P., Hui G.S., Baisor M., and Alpers M.P. Assessment of the role of naturally acquired antibody levels to Plasmodium falciparum merozoite surface protein 1 in protecting Papua New Guinean children from malaria morbidity. Am. J. Trop. Med. Hyg. 54 (1996) 443-448
3. Blackman M.J., Scott F.T., Shai S., and Holder A.A. Antibodies inhibit the protease-mediated processing of a malaria merozoite surface protein. J. Exp. Med. 180 (1994) 389-393
4. Bouharoun-Tayoun H., and Druilhe P. Plasmodium falciparum malaria: evidence for an isotype imbalance which may be responsible for delayed acquisition of protective immunity. Infect. Immun. 60 (1992) 1473-1481
5. Bouharoun-Tayoun H., Oeuvray C., Lunel F., and Druilhe P. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J. Exp. Med. 182 (1995) 409-418
6. Briët, O.J.T., Gunewardena, D.M.,. vander Hoek, W., Amarasinghe, P.M., 2003. Sri Lanka malaria maps. Malaria Journal 2, 22. [Online.] http://www.malariajournal.com/content/2/1/22.
7. Carter R., and Mendis K.N. Evolutionary and historical aspects of the burden of malaria. Clin. Microbiol. Rev. 15 (2002) 564-594
8. Chang S.P., Case S.E., Gosnell W.L., Hashimoto A., Kramer K.J., Tam L.Q., Hashiro C.Q., Naikaidi C.M., Gibson H.L., Lee-Ng C.T., Barr P.J., Yokota B.T.N., and Hui G.S. A recombinant baculovirus 42-kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria. Infect. Immun. 61 (1996) 2462-2467
9. Chitarra V., Holm I., Bentley G.A., Petres S., and Longacre S. The crystal structure of C-terminal merozoite surface protein 1 at 1.8 Å resolution, a highly protective malaria vaccine candidate. Mol. Cell 3 (1999) 457-464
10. del Portillo H.A., Gysin J., Mattei D.M., Khouri E., Udagama P.V., Mendis K.N., and David P.H. Plasmodium vivax: cloning and expression of a major blood-stage surface antigen. Exp. Parasitol. 67 (1988) 346-353
11. del Portillo H.A., Longacre S., Khouri E., and David P.H. Primary structure of the merozoite surface antigen 1 of Plasmodium vivax reveals sequence conserved between different Plasmodium species. Proc. Natl. Acad. Sci. USA 88 (1991) 4030-4034
12. Dua V.K., Kar P.K., and Sharma V.P. Chloroquine resistant Plasmodium vivax malaria. Trop. Med. Int. Health 1 (1996) 816-817
13. 19, the carboxy-terminal fragment of the major merozoite surface protein of Plasmodium falciparum. Infect. Immun. 63 (1995) 456-466
14. Egan A., Waterfall M., Pinder M., Holder A., and Riley E. Characterization of human T- and B-cell epitopes in the C-terminus of Plasmodium falciparum Merozoite Surface Protein 1: evidence for poor T-cell recognition of polypeptides with numerous disulfide bonds. Infect. Immun. 65 (1997) 3024-3031
15. Egan A.F., Blackman M.J., and Kaslow D.C. Vaccine efficacy of recombinant Plasmodium falciparum Merozoite Surface Protein 1 in malaria-naive, -exposed, and/or -rechallenged Aotus vociferans monkeys. Infect. Immun. 68 (2000) 1418-1427
16. Ferreira M.U., Kimura E.A.S., Katzin A.M., Santos-Neto L.L., Ferrari J.O., Villalobos J.M., and de Carvalho M.E. The IgG-subclass distribution of naturally acquired antibodies to Plasmodium falciparum, in relation to malaria exposure and severity. Ann. Trop. Med. Parasitol. 92 (1998) 245-256
17. Fonseka J., and Mendis K.N. A metropolitan hospital in a non-endemic area provides a sampling pool for epidemiological studies on vivax malaria in Sri Lanka. Trans. R. Soc. Trop. Med. Hyg. 81 (1987) 360-364
18. Galinski M.R., and Barnwell J.W. Plasmodium vivax: merozoite, invasion of reticulocytes and consideration for malaria vaccine development. Parasitol. Today 12 (1996) 20-29
19. Gibson H.L., Tucker J.E., Kaslow D.C., Krettli A.U., Collins W.E., Kiefer M.C., Bathurst I.C., and Barr P.J. Structure and expression of the gene for Pv200, a major blood-stage surface antigen of Plasmodium vivax. Mol. Biochem. Parasitol 50 (1992) 325-334
20. Gunewardena D.M., Carter R., and Mendis K.N. Patterns of acquired anti-malarial immunity in Sri Lanka. Mem. Inst. Oswaldo. Cruz. 89 (1994) 61-63
21. Holm I., Nato F., Medis K.N., and Longacre S. Characterization of C-terminal merozoite surface Protein-1 baculovirus recombinant proteins from Plasmodium vivax and Plasmodium cynomolgi as recognized by the natural anti-parasite immune response. Mol. Biochem. Parasitol. 89 (1997) 313-319
22. Kumaratilake L., and Ferrante A. Opsonization and phagocytosis of Plasmodium falciparum merozoites measured by flow cytometry. Clin. Diag. Lab. Immun. 7 (2000) 9-13
23. Longacre S., Mendis K.N., and David P.H. Plasmodium vivax merozoite surface protein 1 C-terminal recombinant proteins in baculovirus. Mol. Biochem. Parasitol. 64 (1994) 191-205
24. Longacre S. The Plasmodium cynomolgi merozoite surface protein 1 C-terminal sequence and its homologies with other Plasmodium species. Mol. Biochem. Parasitol. 74 (1995) 105-111
25. Mendis C., Gamage-Mendis A.C., De Zoysa A.P.K., Abhayawardena T.A., Carter R., Herath P.R.J., and Mendis K.N. Characteristics of malaria transmission in Kataragama, Sri Lanka: a focus for immuno-epidemiological studies. Am. J. Trop. Med. Hyg. 42 (1990) 298-308
26. Mendis C., Giudice G.D., Gamage-Mendis A.C., Tougne C., Pessi A., Weerasinghe S., Carter R., and Mendis K.N. Anti-circumsporozoite protein antibodies measure age related exposure to malaria in Kataragama, Sri Lanka. Parasite Immunol. 14 (1992) 75-86
27. Mendis K., Sina B.J., Marchesini P., and Carter R. The neglected burden of Plasmodium vivax malaria. Am. J. Trop. Med. Hyg. 64 (2001) 97-106
28. 19 are a major component of the invasion-inhibitory response in individuals immune to malaria. J. Exp. Med. 193 (2001) 1403-1412
29. Perera K.L.R.L., Handunnetti S.M., Holm I., Longacre S., and Mendis K. Baculovirus merozoite surface protein 1 C-terminal recombinant antigens are highly protective in a natural primate model for human Plasmodium vivax malaria. Infect. Immun. 66 (1998) 1500-1506
30. Perraut R., Marrama L., Diouf B., Sokhna C., Tall A., Nabeth P., Trape J., Longacre S., and Mercereau-Puijalon O. Antibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a senagalese village. J. Exp. Med. 191 (2005) 264-271
31. Pizarro J.C., Chitarra V., Verger D., Holm I., Petres S., Dartevelle S., Nato F., Longacre S., and Bentley G.A. Crystal structure of a Fab complex formed with PfMSP1-19, The C-terminal fragment of merozoite surface protein 1 from Plasmodium falciparum: a malaria vaccine candidate. J. Mol. Biol. 328 (2003) 1091-1103
32. Putaporntip C., Jongwutiwes S., Sakihama N., Ferreira M.U., Kho W., Kaneko A., Kanbara H., Hattori T., and Tanabe K. Mosaic organization and heterogeneity in frequency of allelic recombination of the Plasmodium vivax merozoite surface protein-1 locus. Proc. Natl. Acad. Sci. USA 99 (2002) 16348-16353
33. Rajendram S., and Jayewickreme S.H. Malaria in Ceylon. Ind. J. Malariol. 5 (1951) 1-2
34. Ranawaka M.B., Munesinghe Y.D., De Silva D.M.R., Carter R., and Mendis K.N. Boosting of transmission-blocking immunity during natural Plasmodium vivax infections in humans depends upon frequent reinfection. Infect. Immun. 56 (1988) 1820-1824
35. Rodriguez L.E., Urquiza M., Ocampo M., Curtidor H., Suárez J., Garcia J., Vera R., Puentes A., López R., Pinto M., Rivera Z., and Patarroyo M.E. Plasmodium vivax MSP-1 peptides have high specific binding activity to human reticulocytes. Vaccine 20 (2002) 1331-1339
36. Rodrigues M.H.C., Rodrigues K.M., Oliveira T.R., Comodo A.N., Rodrigues M.M., Kocken C.H.M., Thomas A.W., and Soares I.S. Antibody response of naturally infected individuals to recombinant Plasmodium vivax apical membrane antigen-1. Int. J. Parasitol. 35 (2005) 185-192
37. Sarthou J.L., Angel G., Aribot G., Rogier C., Dieye A., Balde A.T., Diatta B., Seignot P., and Roussilhon C. Prognostic value of anti-Plasmodium falciparum-specific immunoglobulin G3, cytokines, and their soluble receptors in West African patients with severe malaria. Infect. Immun. 65 (1997) 3271-3276
38. 19) recognized by human antibodies. Parasite Immunol. 17 (1995) 269-275
39. Shi Y.P., Sayed U., Qari S.H., Roberts J.M., Udayakumara V., Oloo A.J., Hawley W.A., Kaslow D.C., Nahlen B.L., and Lal A.A. Natural immune response to the C-terminal 19-kDa domain of Plasmodium falciparum merozoite surface protein 1. Infect. Immun. 60 (1996) 2716-2723
40. Soares I.S., Levitus G., Souza J.M., Del Portillo H.A., and Rodrigues M.M. Acquired immune responses to the N- and C-terminal regions of Plasmodium vivax merozoite surface protein 1 in individuals exposed to malaria. Infect. Immun. 65 (1997) 606-1614
41. Soares I.S., Cunha M.G.D., Silva M.N., Souza J.M., Del Portillo H.A., and Rodrigues M.M. Longevity of naturally acquired antibody responses to the N- and C-terminal regions of Plasmodium vivax merozoite surface protein 1. Am. J. Trop. Med. Hyg. 60 (1999) 357-363
42. Tian J.H., Kumar S., Kaslow D.C., and Miller L.H. Comparison of protection induced by immunization with recombinant proteins from different regions of merozoite surface protein 1 of Plasmodium yoelii. Infect. Immun. 65 (1997) 3032-3036
43. Udagama P.V., David P.H., Peiris J.S.M., Ariyaratne Y.G., Perera K.L.R.L., and Mendis K.N. Demonstration of antigenic polymorphism in Plasmodium vivax malaria with a panel of 30 monoclonal antibodies. Infect. Immun. 55 (1987) 2604-2611
44. Wickramarachchi T., Premaratne P.H., Perera K.L.R.L., Bandara S., Kocken C.H.M., Thomas A.W., Handunnetti S.M., and Udagama-Randeniya P.V. Natural human antibody responses to Plasmodium vivax Apical Membrane Antigen 1 under low transmission and unstable malaria conditions in Sri Lanka. Infect. Immun. 74 (2006) 798-801